<DOC>
	<DOCNO>NCT01260181</DOCNO>
	<brief_summary>This single arm , open-label study evaluate efficacy safety erlotinib ( Tarceva ) participant locally advance metastatic non-small cell lung cancer ( NSCLC ) epidermal growth factor receptor ( EGFR ) mutation .</brief_summary>
	<brief_title>A Study Erlotinib Participants With Locally Advanced Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Locally advanced metastatic NSCLC EGFR mutation Measurable disease accord RECIST criterion Adequate hematological , renal liver function Previous chemotherapy therapy EGFR metastatic disease Symptomatic cerebral metastasis Preexisting disease lung parenchyma lung fibrosis , lymphangitic carcinomatosis History another malignancy except carcinoma insitu cervix , adequately treat basal cell skin carcinoma , radically treat prostate carcinoma good prognosis Concomitant use coumarins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>